16 September 2026 editorial review · Item
Imatinib (tyrosine kinase inhibitor): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: Imatinib randomized primary outcome used a one-sided test; benefit at 12 months not sustained 24 months. Frequent dose modification/discontinuation supports restrained safety interpretation.
- Registry NCT01781975: COMPLETED; updated 2020-02-11; enrollment 67 (ACTUAL); primary completion 2017-05 (ACTUAL); results posted.
- Primary publication/regulatory sources checked or consulted: S2213-8587%2821%2900139-X; 021588s060lbl.pdf.